Incyte Corporation (BVMF:I1NC34)

Market Cap	111.07B +34.3%
Revenue (ttm)	25.65B +18.1%
Net Income	6.33B +3,559.2%
EPS	31.46 +3,878.0%
Shares Out	n/a
PE Ratio	17.53
Forward PE	13.40
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1
Average Volume	62
Open	278.28
Previous Close	268.65
Day's Range	278.28 - 278.28
52-Week Range	170.00 - 299.88
Beta	n/a
RSI	55.15
Earnings Date	Feb 10, 2026

About Incyte

Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics in the United States, Europe, Canada, and Japan. The company offers JAKAFI (ruxolitinib) for the treatment of intermediate or high-risk myelofibrosis, polycythemia vera, and steroid-refractory acute graft-versus-host disease; MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab) for treating relapsed or refractory diffuse large B-cell lymphoma; PEMAZYRE (pemigatinib), a selective fibroblast growth factor receptor kinase inhib...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 1991
• Employees: 2,617
• Stock Exchange: Brazil Stock Exchange
• Ticker Symbol: I1NC34

Financial Performance

In 2024, Incyte's revenue was $4.24 billion, an increase of 14.76% compared to the previous year's $3.70 billion. Earnings were $32.62 million, a decrease of -94.54%.

Financial numbers in USD